US 11267812
KRAS G12C inhibitors
granted A61PA61P35/00A61P35/02
Quick answer
US patent 11267812 (KRAS G12C inhibitors) held by Mirati Therapeutics, Inc. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 34
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00